Oxygenated lipid signaling in tumor-associated macrophages—focus on colon cancer

1.

Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., et al. (2015). Colorectal cancer. Nature Reviews Disease Primers. https://doi.org/10.1038/nrdp.2015.65.

2.

Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., et al. (2017). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncology, 3(4), 524–548. https://doi.org/10.1001/jamaoncol.2016.5688.PubMedCrossRef

3.

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7–30. https://doi.org/10.3322/caac.21442.CrossRef

4.

White, A., Joseph, D., Rim, S. H., Johnson, C. J., Coleman, M. P., & Allemani, C. (2017). Colon cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer, 123(S24), 5014–5036. https://doi.org/10.1002/cncr.31076.PubMedCrossRef

5.

Dulai, P. S., Sandborn, W. J., & Gupta, S. (2016). Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management. Cancer Prevention Research, 9(12), 887–894. https://doi.org/10.1158/1940-6207.CAPR-16-0124.PubMedCrossRef

6.

Saleh, M., & Trinchieri, G. (2010). Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nature Reviews Immunology, 11(1), 9–20. https://doi.org/10.1038/nri2891.PubMedCrossRef

7.

Ma, H., Brosens, L., Offerhaus, J. G. A., Giardiello, F. M., de Leng, W., & Montgomery, E. A. (2018). Pathology and genetics of hereditary colorectal cancer. Pathology, 50(1), 49–59. https://doi.org/10.1016/j.pathol.2017.09.004.PubMedCrossRef

8.

Lasry, A., Zinger, A., & Ben-Neriah, Y. (2016). Inflammatory networks underlying colorectal cancer. Nature Immunology, 17(3), 230–240. https://doi.org/10.1038/ni.3384.PubMedCrossRef

9.

World Cancer Research Fund/American Institute for Cancer Research. (2018) Continuous update project report: diet, nutrition, physical activity, and colorectal cancer. Available from: https://www.wcrf.org/int/continuous-update-project/cup-findings-reports/colorectal-cancer. Accessed 4/19/18.

10.

Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature, 454(7203), 428–435. https://doi.org/10.1038/nature07201.PubMedCrossRef

11.

Aran, D., Lasry, A., Zinger, A., Biton, M., Pikarsky, E., Hellman, A., et al. (2016). Widespread parainflammation in human cancer. Genome Biology, 17(1), 145. https://doi.org/10.1186/s13059-016-0995-z. PubMedPubMedCentralCrossRef

12.

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444. https://doi.org/10.1038/nature07205.PubMedCrossRef

13.

Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010). Inflammation and colon cancer. Gastroenterology, 138(6), 2101–2114. https://doi.org/10.1053/j.gastro.2010.01.058.PubMedCrossRef

14.

Palucka, A. K., & Coussens, L. M. (2016). The basis of oncoimmunology. Cell, 164(6), 1233–1247. https://doi.org/10.1016/j.cell.2016.01.049.PubMedPubMedCentralCrossRef

15.

Sharma, P., & Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell, 161(2), 205–214. https://doi.org/10.1016/j.cell.2015.03.030.PubMedPubMedCentralCrossRef

16.

Talmadge, J. E., Donkor, M., & Scholar, E. (2007). Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Reviews, 26(3-4), 373–400. https://doi.org/10.1007/s10555-007-9072-0.PubMedCrossRef

17.

Hackl, H., Charoentong, P., Finotello, F., & Trajanoski, Z. (2016). Computational genomics tools for dissecting tumour-immune cell interactions. Nature Reviews. Genetics, 17(8), 441–458. https://doi.org/10.1038/nrg.2016.67.PubMedCrossRef

18.

Gentles, A. J., Newman, A. M., Liu, C., Bratman, S. V., Feng, W., Kim, D., et al. (2015). The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine, 21(8), 938–945. https://doi.org/10.1038/nm.3909.PubMedPubMedCentralCrossRef

19.

Fridman, W. H., Zitvogel, L., Sautès-Fridman, C., & Kroemer, G. (2017). The immune contexture in cancer prognosis and treatment. Nature Reviews. Clinical Oncology, 14(12), 717–734. https://doi.org/10.1038/nrclinonc.2017.101.PubMedCrossRef

20.

Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., et al. (2014). Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. The Journal of Pathology, 232(2), 199–209. https://doi.org/10.1002/path.4287.PubMedCrossRef

21.

Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013). The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity, 39(1), 11–26. https://doi.org/10.1016/j.immuni.2013.07.008.PubMedCrossRef

22.

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313(5795), 1960–1964. https://doi.org/10.1126/science.1129139.PubMedCrossRef

23.

Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., et al. (2013). Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity, 39(4), 782–795. https://doi.org/10.1016/j.immuni.2013.10.003.PubMedCrossRef

24.

Angelova, M., Charoentong, P., Hackl, H., Fischer, M. L., Snajder, R., Krogsdam, A. M., et al. (2015). Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biology, 16(1), 64–80. https://doi.org/10.1186/s13059-015-0620-6. PubMedPubMedCentralCrossRef

25.

Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., et al. (2017). Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Reports, 18(1), 248–262. https://doi.org/10.1016/j.celrep.2016.12.019.PubMedCrossRef

26.

Mowat, A. M., Scott, C. L., & Bain, C. C. (2017). Barrier-tissue macrophages: functional adaptation to environmental challenges. Nature Medicine, 23(11), 1258–1270. https://doi.org/10.1038/nm.4430.PubMedCrossRef

27.

Gordon, S., Plüddemann, A., & Martinez Estrada, F. (2014). Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunological Reviews, 262(1), 36–55. https://doi.org/10.1111/imr.12223.PubMedPubMedCentralCrossRef

28.

Gordon, S., & Martinez, F. O. (2010). Alternative activation of macrophages: mechanism and functions. Immunity, 32(5), 593–604. https://doi.org/10.1016/j.immuni.2010.05.007.PubMedCrossRef

29.

Bain, C. C., & Mowat, A. (2014). Macrophages in intestinal homeostasis and inflammation. Immunological Reviews, 260(1), 102–117. https://doi.org/10.1111/imr.12192.PubMedPubMedCentralCrossRef

30.

Joeris, T., Müller-Luda, K., Agace, W. W., & Mowat, A. M. (2017). Diversity and functions of intestinal mononuclear phagocytes. Mucosal Immunology, 10(4), 845–864. https://doi.org/10.1038/mi.2017.22.PubMedCrossRef

31.

Freire-de-Lima, C. G., Xiao, Y., Gardai, S. J., Bratton, D. L., Schiemann, W. P., & Henson, P. M. (2006). Apoptotic cells, through transforming growth factor-β, coordinately induce anti-inflammatory and suppress proinflammatory eicosanoid and no synthesis in murine macrophages. Journal of Biological Chemistry, 281(50), 38376–38384. https://doi.org/10.1074/jbc.M605146200.PubMedCrossRef

32.

Dalli, J., & Serhan, C. N. (2012). Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood, 120(15), e60–e72. https://doi.org/10.1182/blood-2012-04-423525.PubMedPubMedCentralCrossRef

33.

Dalli, J., & Serhan, C. (2016). Macrophage proresolving mediators—the when and where. Microbiology Spectrum, 4(3). https://doi.org/10.1128/microbiolspec.MCHD-0001-2014

34.

Dalli, J., & Serhan, C. N. (2017). Pro-resolving mediators in regulating and conferring macrophage function. Frontiers in Immunology, 8, 1400. https://doi.org/10.3389/fimmu.2017.01400.PubMedPubMedCentralCrossRef

35.

Norris, P. C., & Dennis, E. A. (2013). A lipidomic perspective on inflammatory macrophage eicosanoid signaling. Advances in Biological Regulation, 54, 99–110. https://doi.org/10.1016/j.jbior.2013.09.009.PubMedCrossRef

36.

Werz, O., Gerstmeier, J., Libreros, S., De la Rosa, X., Werner, M., Norris, P. C., et al. (2018). Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nature Communications, 9(1), 59. https://doi.org/10.1038/s41467-017-02538-5.PubMedPubMedCentralCrossRef

37.

Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000). M-1/M-2 macrophages and the Th1/Th2 paradigm. Journal of Immunology (Baltimore, Md.: 1950), 164(12), 6166–6173.CrossRef

38.

Kim, I., & Zhang, X. (2016). One microenvironment does not fit all: heterogeneity beyond cancer cells. Cancer and Metastasis Reviews, 35(4), 601–629. https://doi.org/10.1007/s10555-016-9643-z.PubMedCrossRef

39.

Balkwill, F. R., Capasso, M., & Hagemann, T. (2012). The tumor microenvironment at a glance. Journal of Cell Science, 125(23), 5591–5596. https://doi.org/10.1242/jcs.116392.PubMedCrossRef

40.

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013). Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology, 14(10), 1014–1022. https://doi.org/10.1038/ni.2703.PubMedPubMedCentralCrossRef

41.

Fearon, D. T. (2016). Immune-suppressing cellular elements of the tumor microenvironment. Annual Review of Cancer Biology, 1(1), 241–255. https://doi.org/10.1146/annurev-cancerbio-050216-034359.CrossRef

42.

Bolli, E., Movahedi, K., Laoui, D., & Ginderachter, J. A. (2017). Novel insights in the regulation and function of macrophages in the tumor microenvironment. Current Opinion in Oncology, 29(1), 55. https://doi.org/10.1097/CCO.0000000000000344.PubMedCrossRef

43.

Maley, C. C., Aktipis, A., Graham, T. A., Sottoriva, A., Boddy, A. M., Janiszewska, M., et al. (2017). Classifying the evolutionary and ecological features of neoplasms. Nature Reviews Cancer, 17(10), 605–619. https://doi.org/10.1038/nrc.2017.69.PubMedPubMedCentralCrossRef

44.

Tauriello, D., & Batlle, E. (2016). Targeting the microenvironment in advanced colorectal cancer. Trends in Cancer, 2(9), 495–504. https://doi.org/10.1016/j.trecan.2016.08.001.PubMedCrossRef

45.

Kiss, M., Gassen, S., Movahedi, K., Saeys, Y., & Laoui, D. (2018). Myeloid cell heterogeneity in cancer: not a single cell alike. Cellular Immunology. https://doi.org/10.1016/j.cellimm.2018.02.008.

46.

Noy, R., & Pollard, J. W. (2014). Tumor-associated macrophages: from mechanisms to therapy. Immunity, 41(1), 4961. https://doi.org/10.1016/j.immuni.2014.06.010.CrossRef

47.

Franklin, R. A., & Li, M. O. (2016). Ontogeny of tumor-associated macrophages and its implication in cancer regulation. Trends in Cancer, 2(1), 20–34. https://doi.org/10.1016/j.trecan.2015.11.004.PubMedPubMedCentralCrossRef

48.

Cortez-Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., et al. (2012). Origins of tumor-associated macrophages and neutrophils. Proceedings of the National Academy of Sciences, 109(7), 2491–2496. https://doi.org/10.1073/pnas.1113744109.CrossRef

49.

Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nature Reviews. Immunology, 12(4), 253–268. https://doi.org/10.1038/nri3175.PubMedPubMedCentralCrossRef

50.

Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016). The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends in Immunology, 37(3), 208–220. https://doi.org/10.1016/j.it.2016.01.004.PubMedPubMedCentralCrossRef

51.

Qian, B.-Z. Z., & Pollard, J. W. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell, 141(1), 39–51. https://doi.org/10.1016/j.cell.2010.03.014.PubMedPubMedCentralCrossRef

52.

Isidro, R. A., & Appleyard, C. B. (2016). Colonic macrophage polarization in homeostasis, inflammation, and cancer. American Journal of Physiology - Gastrointestinal and Liver. Physiology, 311(1), 73. https://doi.org/10.1152/ajpgi.00123.2016.CrossRef

53.

Soncin, I., Sheng, J., Chen, Q., Foo, S., Duan, K., Lum, J., et al. (2018). The tumour microenvironment creates a niche for the self-renewal of tumour-promoting macrophages in colon adenoma. Nature Communications, 9(1), 582. https://doi.org/10.1038/s41467-018-02834-8.PubMedPubMedCentralCrossRef

54.

Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., den Bossche, J., et al. (2010). Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Research, 70(14), 5728–5739. https://doi.org/10.1158/0008-5472.CAN-09-4672.PubMedCrossRef

55.

Mantovani, A., Sozzani, S., Locati, M., Allavena, P., & Sica, A. (2002). Macrophage polarization: tumorassociated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 23(11), 549–555. https://doi.org/10.1016/S1471-4906(02)02302-5.PubMedCrossRef

56.

Murray, P. J. (2018). Nonresolving macrophage-mediated inflammation in malignancy. The FEBS Journal, 285(4), 641–653. https://doi.org/10.1111/febs.14210.PubMedCrossRef

57.

Evans, R., & Alexander, P. (1970). Cooperation of immune lymphoid cells with macrophages in tumour immunity. Nature, 228(5272), 620–622.PubMedCrossRef

58.

Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017). Tumour-associated macrophages as treatment targets in oncology. Nature Reviews. Clinical Oncology, 14(7), 399–416. https://doi.org/10.1038/nrclinonc.2016.217.PubMedPubMedCentralCrossRef

59.

Müller-Quernheim, U., Potthast, L., Müller-Quernheim, J., & Zissel, G. (2012). Tumor-cell co-culture induced alternative activation of macrophages is modulated by interferons in vitro. Journal of Interferon & Cytokine Research, 32(4), 169–177. https://doi.org/10.1089/jir.2011.0020.CrossRef

60.

Kuen, J., Darowski, D., Kluge, T., & Majety, M. (2017). Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model. PLoS ONE, 12(7). https://doi.org/10.1371/journal.pone.0182039.

61.

Spranger, S., & Gajewski, T. F. (2018). Impact of oncogenic pathways on evasion of antitumour immune responses. Nature Reviews Cancer, 18(3), 139–147. https://doi.org/10.1038/nrc.2017.117.PubMedCrossRef

62.

Spranger, S., & Gajewski, T. F. (2018). Mechanisms of tumor cell–intrinsic immune evasion. Annual Review of Cancer Biology, 2(1), 213–228. https://doi.org/10.1146/annurev-cancerbio-030617-050606.CrossRef

63.

Wellenstein, M. D., & de Visser, K. E. (2018). Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity, 48(3), 399–416. https://doi.org/10.1016/j.immuni.2018.03.004.PubMedCrossRef

64.

Iglesia, M. D., Parker, J. S., Hoadley, K. A., Serody, J. S., Perou, C. M., & Vincent, B. G. (2016). Genomic analysis of immune cell infiltrates across 11 tumor types. Journal of the National Cancer Institute, 108(11). https://doi.org/10.1093/jnci/djw144.

65.

Erreni, M., Mantovani, A., & Allavena, P. (2011). Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenvironment, 4(2), 141–154. https://doi.org/10.1007/s12307-010-0052-5.PubMedCrossRef

66.

Norton, S. E., Dunn, E. T. J., McCall, J. L., Munro, F., & Kemp, R. A. (2016). Gut macrophage phenotype is dependent on the tumor microenvironment in colorectal cancer. Clinical & Translational Immunology, 5(4). doi:https://doi.org/10.1038/cti.2016.21.

67.

Forssell, J., Öberg, Å., Henriksson, M. L., Stenling, R., Jung, A., & Palmqvist, R. (2007). High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clinical Cancer Research, 13(5), 1472–1479. https://doi.org/10.1158/1078-0432.CCR-06-2073.PubMedCrossRef

68.

Funada, Y., Noguchi, T., Kikuchi, R., Takeno, S., Uchida, Y., & Gabbert, H. E. (2003). Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncology Reports, 10(2), 309–313.PubMed

69.

Zhou, Q., Peng, R.-Q. Q., Wu, X.-J. J., Xia, Q., Hou, J.-H. H., Ding, Y., et al. (2010). The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. Journal of Translational Medicine, 8, 13. https://doi.org/10.1186/1479-5876-8-13.PubMedPubMedCentralCrossRef

70.

Norton, S. E., Ward-Hartstonge, K. A., Taylor, E. S., & Kemp, R. A. (2015). Immune cell interplay in colorectal cancer prognosis. World Journal of Gastrointestinal Oncology, 7(10), 221. https://doi.org/10.4251/wjgo.v7.i10.221.PubMedPubMedCentralCrossRef

71.

Kang, J. C., Chen, J. S., Lee, C. H., Chang, J. J., & Shieh, Y. S. (2010). Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. Journal of Surgical Oncology, 102(3), 242–248. https://doi.org/10.1002/jso.21617.PubMedCrossRef

72.

Berthenet, K., Boudesco, C., Collura, A., Svrcek, M., Richaud, S., Hammann, A., et al. (2016). Extracellular HSP110 skews macrophage polarization in colorectal cancer. OncoImmunology, 5(7). https://doi.org/10.1080/2162402X.2016.1170264.

73.

Herbeuval, J.-P., Lelievre, E., Lambert, C., Dy, M., & Genin, C. (2004). Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. The Journal of Immunology, 172(7), 4630–4636. https://doi.org/10.4049/jimmunol.172.7.4630.PubMedCrossRef

74.

Srivatsa, S., Paul, M. C., Cardone, C., Holcmann, M., Amberg, N., Pathria, P., et al. (2017). EGFR in tumor-associated myeloid cells promotes development of colorectal cancer in mice and associates with outcomes of patients. Gastroenterology, 153(1), 178–190. https://doi.org/10.1053/j.gastro.2017.03.053.PubMedPubMedCentralCrossRef

75.

Waniczek, D., Lorenc, Z., Śnietura, M., Wesecki, M., Kopec, A., & Muc-Wierzgoń, M. (2017). Tumorassociated macrophages and regulatory T cells infiltration and the clinical outcome in colorectal cancer. Archivum Immunologiae et Therapiae Experimentalis, 65(5), 445–454. https://doi.org/10.1007/s00005-017-0463-9.PubMedPubMedCentralCrossRef

76.

Herrera, M., Herrera, A., Domínguez, G., Silva, J., García, V., García, J. M., et al. (2013). Cancerassociated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Science, 104(4), 437–444. https://doi.org/10.1111/cas.12096.PubMedCrossRef

77.

Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L., Goedemans, R., Jha, V., et al. (2013). Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Research, 73(8), 2480–2492 https://doi.org/10.1158/0008-5472.CAN-12-3542.PubMedCrossRef

78.

Burdge, G. C., & Calder, P. C. (2015). Introduction to fatty acids and lipids. World Review of Nutrition and Dietetics, 112, 1–16. https://doi.org/10.1159/000365423.PubMedCrossRef

79.

Castro, L. F., Tocher, D. R., & Monroig, O. (2016). Long-chain polyunsaturated fatty acid biosynthesis in chordates: Insights into the evolution of Fads and Elovl gene repertoire. Progress in Lipid Research, 62, 25–40. https://doi.org/10.1016/j.plipres.2016.01.001.PubMedCrossRef

80.

Fritsche, K. L. (2015). The science of fatty acids and inflammation. Advances in Nutrition: An International Review Journal, 6(3), 293S–301S. https://doi.org/10.3945/an.114.006940.CrossRef

81.

Berquin, I. M., Edwards, I. J., Kridel, S. J., & Chen, Y. Q. (2011). Polyunsaturated fatty acid metabolism in prostate cancer. Cancer and Metastasis Reviews, 30(3-4), 295–309. https://doi.org/10.1007/s10555-011-9299-7.PubMedCrossRef

82.

Pawlosky, R. J., Hibbeln, J. R., Novotny, J. A., & Salem, N. (2001). Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. Journal of Lipid Research, 42(8), 1257–1265.PubMed

83.

Beilstein, F., Carrière, V., Leturque, A., & Demignot, S. (2016). Characteristics and functions of lipid droplets and associated proteins in enterocytes. Experimental Cell Research, 340(2), 172–179. https://doi.org/10.1016/j.yexcr.2015.09.018.PubMedCrossRef

84.

Hussain, M. M. (2014). Intestinal lipid absorption and lipoprotein formation. Current Opinion in Lipidology, 25(3), 200. https://doi.org/10.1097/MOL.0000000000000084.PubMedPubMedCentralCrossRef

85.

Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015). New Insights into the regulation of chylomicron production. Annual Review of Nutrition, 35, 265–294. https://doi.org/10.1146/annurev-nutr-071714-034338.PubMedCrossRef

86.

Hou, T. Y., Davidson, L. A., Kim, E., Fan, Y.-Y. Y., Fuentes, N. R., Triff, K., et al. (2016). Nutrient-gene interaction in colon cancer, from the membrane to cellular physiology. Annual Review of Nutrition, 36, 543–570. https://doi.org/10.1146/annurev-nutr-071715-051039.PubMedPubMedCentralCrossRef

87.

Hajri, T., & Abumrad, N. A. (2002). Fatty acid transport across membranes: relevance to nutrition and metabolic pathology. Annual Review of Nutrition, 22, 383–415. https://doi.org/10.1146/annurev.nutr.22.020402.130846.PubMedCrossRef

88.

Alvarez-Curto, E., & Milligan, G. (2016). Metabolism meets immunity: the role of free fatty acid receptors in the immune system. Biochemical Pharmacology, 114, 3–13. https://doi.org/10.1016/j.bcp.2016.03.017.PubMedCrossRef

89.

Milligan, G., Shimpukade, B., Ulven, T., & Hudson, B. D. (2017). Complex pharmacology of free fatty acid receptors. Chemical Reviews, 117(1), 67–110. https://doi.org/10.1021/acs.chemrev.6b00056.PubMedCrossRef

90.

Shindou, H., Hishikawa, D., Harayama, T., Eto, M., & Shimizu, T. (2013). Generation of membrane diversity by lysophospholipid acyltransferases. Journal of Biochemistry, 154(1), 21–28. https://doi.org/10.1093/jb/mvt048.PubMedCrossRef

91.

Dennis, E. A., Cao, J., Hsu, Y.-H. H., Magrioti, V., & Kokotos, G. (2011). Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chemical Reviews, 111(10), 6130–6185. https://doi.org/10.1021/cr200085w.PubMedPubMedCentralCrossRef

92.

Dennis, E. A., & Norris, P. C. (2015). Eicosanoid storm in infection and inflammation. Nature Reviews Immunology, 15(8), 511–523. https://doi.org/10.1038/nri3859.PubMedPubMedCentralCrossRef

93.

Murase, R., Sato, H., Yamamoto, K., Ushida, A., Nishito, Y., Ikeda, K., et al. (2016). Group X secreted phospholipase A2 releases ω3 polyunsaturated fatty acids, suppresses colitis, and promotes sperm fertility. Journal of Biological Chemistry, 291(13), 6895–6911. https://doi.org/10.1074/jbc.M116.715672.PubMedCrossRef

94.

Schneider, C., Pratt, D. A., Porter, N. A., & Brash, A. R. (2007). Control of oxygenation in lipoxygenase and cyclooxygenase catalysis. Chemistry & Biology, 14(5), 473–488. https://doi.org/10.1016/j.chembiol.2007.04.007.CrossRef

95.

Oliw, E. (1994). Oxygenation of polyunsaturated fatty acids by cytochrome p450 monooxygenases. Progress in Lipid Research, 33(3), 329–354.PubMedCrossRef

96.

Spector, A. A., & Kim, H.-Y. (2014). Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism. Biochimica et Biophysica Acta, 1851(4), 356–365. https://doi.org/10.1016/j.bbalip.2014.07.020.PubMedPubMedCentralCrossRef

97.

Johnson, A. L., Edson, K. Z., Totah, R. A., & Rettie, A. E. (2015). Cytochrome P450 ω-hydroxylases in inflammation and cancer. Advances in Pharmacology (San Diego, Calif.), 74, 223–262. https://doi.org/10.1016/bs.apha.2015.05.002.CrossRef

98.

Ivanov, I., Kuhn, H., & Heydeck, D. (2015). Structural and functional biology of arachidonic acid 15-lipoxygenase-1 (ALOX15). Gene, 573(1), 1–32. https://doi.org/10.1016/j.gene.2015.07.073.PubMedCrossRef

99.

Vangaveti, V. N., Jansen, H., Kennedy, R., & Malabu, U. H. (2016). Hydroxyoctadecadienoic acids: oxidised derivatives of linoleic acid and their role in inflammation associated with metabolic syndrome and cancer. European Journal of Pharmacology, 785, 70–76. https://doi.org/10.1016/j.ejphar.2015.03.096.PubMedCrossRef

100.

Soler, J., Saura, P., García-López, D., Masgrau, L., Lluch, J. M., & González-Lafont, À. (2015). How can linoleic acid be the preferential substrate of the enzyme 15-lipoxygenase-1? A QM/MM approach. The Journal of Physical Chemistry B, 120(8), 1950–1960. https://doi.org/10.1021/acs.jpcb.5b09897.PubMedCrossRef

101.

Harizi, H., Corcuff, J.-B., & Gualde, N. (2008). Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends in Molecular Medicine, 14(10), 461–469. https://doi.org/10.1016/j.molmed.2008.08.005.PubMedCrossRef

102.

Marnett, L. J., Rowlinson, S. W., Goodwin, D. C., Kalgutkar, A. S., & Lanzo, C. A. (1999). Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. The Journal of Biological Chemistry, 274(33), 22903–22906.PubMed

103.

Powell, W. S., & Rokach, J. (2015). Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1851(4), 340–355. https://doi.org/10.1016/j.bbalip.2014.10.008.CrossRef

104.

Wan, M., Tang, X., Stsiapanava, A., & Haeggström, J. Z. (2017). Biosynthesis of leukotriene B4. Seminars in Immunology, 33, 3–15. https://doi.org/10.1016/j.smim.2017.07.012.PubMedCrossRef

105.

Haeggström, J. Z., & Funk, C. D. (2011). Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chemical Reviews, 111(10), 5866–5898. https://doi.org/10.1021/cr200246d.PubMedCrossRef

106.

Romano, M., Cianci, E., Simiele, F., & Recchiuti, A. (2015). Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. European Journal of Pharmacology, 760, 49–63. https://doi.org/10.1016/j.ejphar.2015.03.083.PubMedCrossRef

107.

Chiang, N., Arita, M., & Serhan, C. N. (2005). Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins, Leukotrienes and Essential Fatty Acids, 73(3-4), 163–177. https://doi.org/10.1016/j.plefa.2005.05.003.CrossRef

108.

Serhan, C. N., & Petasis, N. A. (2011). Resolvins and protectins in inflammation resolution. Chemical Reviews, 111(10), 5922–5943. https://doi.org/10.1021/cr100396c.PubMedPubMedCentralCrossRef

109.

Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R., & Serhan, C. N. (2011). Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. The Journal of Clinical Investigation, 121(2), 569–581. https://doi.org/10.1172/JCI42545.PubMedPubMedCentralCrossRef

110.

Serhan, C. N., Fredman, G., Yang, R., Karamnov, S., Belayev, L. S., Bazan, N. G., et al. (2011). Novel proresolving aspirin-triggered DHA pathway. Chemistry & Biology, 18(8), 976–987. https://doi.org/10.1016/j.chembiol.2011.06.008.CrossRef

111.

Dalli, J., Ramon, S., Norris, P. C., Colas, R. A., & Serhan, C. N. (2015). Novel proresolving and tissueregenerative resolvin and protectin sulfido-conjugated pathways. The FASEB Journal, 29(5), 2120–2136. https://doi.org/10.1096/fj.14-268441.PubMedPubMedCentralCrossRef

112.

Serhan, C. N., Chiang, N., & Dalli, J. (2017). New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Molecular Aspects of Medicine. https://doi.org/10.1016/j.mam.2017.08.002.

113.

Dalli, J., Chiang, N., & Serhan, C. N. (2014). Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection. Proceedings of the National Academy of Sciences, 111(44), E4753–E4761. https://doi.org/10.1073/pnas.1415006111.CrossRef

114.

de la Rosa, X., Norris, P. C., Chiang, N., Rodriguez, A. R., Spur, B. W., & Serhan, C. N. (2018). Identification and complete stereochemical assignments of the new resolvin conjugates in tissue regeneration in human tissues that stimulate proresolving phagocyte functions and tissue regeneration. The American Journal of Pathology, 188(4), 950–966. https://doi.org/10.1016/j.ajpath.2018.01.004.PubMedCrossRef

115.

Simmons, D. L., Botting, R. M., & Hla, T. (2004). Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological Reviews, 56(3), 387–437. https://doi.org/10.1124/pr.56.3.3.PubMedCrossRef

116.

Seo, M.-J. J., & Oh, D.-K. K. (2017). Prostaglandin synthases: molecular characterization and involvement in prostaglandin biosynthesis. Progress in Lipid Research, 66, 50–68. https://doi.org/10.1016/j.plipres.2017.04.003.PubMedCrossRef

117.

Hata, A. N., & Breyer, R. M. (2004). Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacology & Therapeutics, 103(2), 147–166. https://doi.org/10.1016/j.pharmthera.2004.06.003.CrossRef

118.

Lecomte, M., Laneuville, O., Ji, C., DeWitt, D. L., & Smith, W. L. (1994). Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. The Journal of Biological Chemistry, 269(18), 13207–13215.PubMed

119.

Clària, J., & Serhan, C. N. (1995). Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proceedings of the National Academy of Sciences, 92(21), 9475–9479. https://doi.org/10.1073/pnas.92.21.9475.CrossRef

120.

Serhan, C. N. (2014). Pro-resolving lipid mediators are leads for resolution physiology. Nature, 510(7503), 92–101. https://doi.org/10.1038/nature13479.PubMedPubMedCentralCrossRef

121.

Ivanov, I., Heydeck, D., Hofheinz, K., Roffeis, J., O'Donnell, V. B., Kuhn, H., & Walther, M. (2010). Molecular enzymology of lipoxygenases. Archives of Biochemistry and Biophysics, 503(2), 161–174. https://doi.org/10.1016/j.abb.2010.08.016.PubMedCrossRef

122.

Ivanov, I., Saam, J., Kuhn, H., & Holzhütter, H. G. (2005). Dual role of oxygen during lipoxygenase reactions. FEBS Journal, 272(10), 2523–2535. https://doi.org/10.1111/j.1742-4658.2005.04673.x.PubMedCrossRef

123.

Kuhn, H., Saam, J., Eibach, S., Holzhütter, H.-G., Ivanov, I., & Walther, M. (2005). Structural biology of mammalian lipoxygenases: enzymatic consequences of targeted alterations of the protein structure. Biochemical and Biophysical Research Communications, 338(1), 93–101. https://doi.org/10.1016/j.bbrc.2005.08.238.PubMedCrossRef

124.

Kuhn, H., Banthiya, S., & van Leyen, K. (2015). Mammalian lipoxygenases and their biological relevance. Biochimica et Biophysica Acta, 1851(4), 308–330. https://doi.org/10.1016/j.bbalip.2014.10.002.PubMedCrossRef

125.

Ackermann, J. A., Hofheinz, K., Zaiss, M. M., & Krönke, G. (2016). The double-edged role of 12/15-Lipoxygenase during inflammation and immunity. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1862(4), 371–381. https://doi.org/10.1016/j.bbalip.2016.07.014.CrossRef

126.

Rådmark, O., Werz, O., Steinhilber, D., & Samuelsson, B. (2015). 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1851(4), 331–339. https://doi.org/10.1016/j.bbalip.2014.08.012.CrossRef

127.

Rådmark, O., & Samuelsson, B. (2009). 5-Lipoxygenase: mechanisms of regulation. Journal of Lipid Research, 50(Supplement), S45–S50. https://doi.org/10.1194/jlr.R800062-JLR200.CrossRef

128.

Cathcart, M.-C. C., Lysaght, J., & Pidgeon, G. P. (2011). Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. Cancer Metastasis Reviews, 30(3-4), 363–385. https://doi.org/10.1007/s10555-011-9324-x.PubMedCrossRef

129.

Moore, G. Y., & Pidgeon, G. P. (2017). Cross-talk between cancer cells and the tumour microenvironment: the role of the 5-lipoxygenase pathway. International Journal of Molecular Sciences, 18(2). doi:https://doi.org/10.3390/ijms18020236

130.

Melstrom, L. G., Bentrem, D. J., Salabat, M. R., Kennedy, T. J., Ding, X.-Z., Strouch, M., et al. (2008). Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clinical Cancer Research, 14(20), 6525–6530. https://doi.org/10.1158/1078-0432.CCR-07-4631.PubMedCrossRef

131.

Calorini, L., Bianchini, F., Mannini, A., Mugnai, G., & Ruggieri, S. (2005). Inhibition of lipoxygenase pathway in macrophages co-cultivated with tumor cells. Cancer Letters, 223(1), 151–158. https://doi.org/10.1016/j.canlet.2004.09.034.PubMedCrossRef

132.

Sorgi, C. A., Zarini, S., Martin, S. A., Sanchez, R. L., Scandiuzzi, R. F., Gijón, M. A., et al. (2017). Dormant 5-lipoxygenase in inflammatory macrophages is triggered by exogenous arachidonic acid. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-11496-3.

133.

Il Lee, S., Zuo, X., & Shureiqi, I. (2011). 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? Cancer Metastasis Reviews, 30(3-4), 481–491. https://doi.org/10.1007/s10555-011-9321-0.PubMedCrossRef

134.

Tian, R., Zuo, X., Jaoude, J., Mao, F., Colby, J., & Shureiqi, I. (2017). ALOX15 as a suppressor of inflammation and cancer: lost in the link. Prostaglandins & Other Lipid Mediators, 132, 77–83. https://doi.org/10.1016/j.prostaglandins.2017.01.002.CrossRef

135.

Zuo, X., Morris, J. S., & Shureiqi, I. (2008). Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells. Journal of Biological Chemistry, 283(46), 31341–31347. https://doi.org/10.1074/jbc.m803729200.PubMedCrossRef

136.

Zuo, X., Peng, Z., Wu, Y., Moussalli, M. J., Yang, X. L., Wang, Y., et al. (2012). Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. Journal of the National Cancer Institute, 104(9), 709–716. https://doi.org/10.1093/jnci/djs187.PubMedPubMedCentralCrossRef

137.

Shureiqi, I., Wojno, K. J., Poore, J. A., Reddy, R. G., Moussalli, M. J., Spindler, S. A., et al. (1999). Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis, 20(10), 1985–1995. https://doi.org/10.1093/carcin/20.10.1985.PubMedCrossRef

138.

Moussalli, M. J., Wu, Y., Zuo, X., Yang, X. L., Wistuba, I., Raso, M. G., et al. (2011). Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion. Cancer Prevention Research, 4(12), 1961–1972. https://doi.org/10.1158/1940-6207.CAPR-10-0280.PubMedCrossRef

139.

Nixon, J. B., Kim, K.-S., Lamb, P. W., Bottone, F. G., & Eling, T. E. (2004). 15-Lipoxygenase-1 has antitumorigenic effects in colorectal cancer. Prostaglandins, Leukotrienes and Essential Fatty Acids, 70(1), 7–15. https://doi.org/10.1016/j.plefa.2003.06.001.CrossRef

140.

Wuest, S., Crucet, M., Gemperle, C., Loretz, C., & Hersberger, M. (2012). Expression and regulation of 12/15-lipoxygenases in human primary macrophages. Atherosclerosis, 225(1), 121–127. https://doi.org/10.1016/j.atherosclerosis.2012.07.022.PubMedCrossRef

141.

Bishop-Bailey, D., Thomson, S., Askari, A., Faulkner, A., & Wheeler-Jones, C. (2014). Lipid-metabolizing CYPs in the regulation and dysregulation of metabolism. Annual Review of Nutrition, 34(1), 261–279. https://doi.org/10.1146/annurev-nutr-071813-105747.PubMedCrossRef

142.

Divanovic, S., Dalli, J., Jorge-Nebert, L. F., Flick, L. M., Gálvez-Peralta, M., Boespflug, N. D., et al. (2013). Contributions of the three CYP1 monooxygenases to pro-inflammatory and inflammation-resolution lipid mediator pathways. The Journal of Immunology, 191(6), 3347–3357. https://doi.org/10.4049/jimmunol.1300699.PubMedCrossRef

143.

Wang, W., Yang, J., Nimiya, Y., Lee, K., Sanidad, K., Qi, W., et al. (2017). ω-3 Polyunsaturated fatty acids and their cytochrome P450-derived metabolites suppress colorectal tumor development in mice. The Journal of Nutritional Biochemistry, 48, 29–35. https://doi.org/10.1016/j.jnutbio.2017.06.006.PubMedCrossRef

144.

Panigrahy, D., Edin, M. L., Lee, C. R., Huang, S., Bielenberg, D. R., Butterfield, C. E., et al. (2012). Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. Journal of Clinical Investigation, 122(1), 178–191. https://doi.org/10.1172/JCI58128.PubMedCrossRef

145.

Wang, W., Zhu, J., Lyu, F., Panigrahy, D., Ferrara, K. W., Hammock, B., et al. (2014). ω-3 Polyunsaturated fatty acids-derived lipid metabolites on angiogenesis, inflammation and cancer. Prostaglandins & Other Lipid Mediators, 113-115(1320). https://doi.org/10.1016/j.prostaglandins.2014.07.002.

146.

Kalsotra, A., & Strobel, H. W. (2006). Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacology & Therapeutics, 112(3), 589–611. https://doi.org/10.1016/j.pharmthera.2006.03.008.CrossRef

147.

Bystrom, J., Wray, J. A., Sugden, M. C., Holness, M. J., Swales, K. E., Warner, T. D., et al. (2011). Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS ONE, 6(10). https://doi.org/10.1371/journal.pone.0026591.

148.

Christmas, P. (2015). Role of cytochrome P450s in inflammation. Advances in Pharmacology (San Diego, Calif.), 74, 163–192. https://doi.org/10.1016/bs.apha.2015.03.005.CrossRef

149.

Gilroy, D. W., Edin, M. L., Maeyer, R., Bystrom, J., Newson, J., Lih, F. B., et al. (2016). CYP450-derived oxylipins mediate inflammatory resolution. Proceedings of the National Academy of Sciences, 113(23), E3240–E3249. https://doi.org/10.1073/pnas.1521453113.CrossRef

150.

Shureiqi, I., Chen, D., Day, S. R., Zuo, X., Hochman, F., Ross, W. A., et al. (2010). Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prevention Research, 3(7), 829–838. https://doi.org/10.1158/1940-6207.capr-09-0110.PubMedCrossRef

151.

Srednicka-Tober, D., Baranski, M., Seal, C., Sanderson, R., Benbrook, C., Steinshamn, H., et al. (2016). Composition differences between organic and conventional meat: a systematic literature review and meta-analysis. The British Journal of Nutrition, 115(6), 994–1011. https://doi.org/10.1017/S0007114515005073.PubMedPubMedCentralCrossRef

152.

Steffen, B. T., Steffen, L. M., Liang, S., Tracy, R., Jenny, N. S., & Tsai, M. Y. (2013). n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis. The British Journal of Nutrition, 110(9), 1664–1671. https://doi.org/10.1017/S0007114513000949.PubMedPubMedCentralCrossRef

153.

Jandacek, R. J. (2017). Linoleic acid: a nutritional quandary. Healthcare (Basel), 5(2). https://doi.org/10.3390/healthcare5020025

154.

Kawahara, I., Mori, T., Goto, K., Fujii, K., Ohmori, H., Kishi, S., et al. (2017). Fatty acids induce stemness in the stromal cells of a CT26 mouse tumor model. Pathobiology, 84(5), 237–242. https://doi.org/10.1159/000471854.PubMedCrossRef

155.

Jurek, D., Udilova, N., Jozkowicz, A., Nohl, H., Marian, B., & Schulte-Hermann, R. (2005). Dietary lipid hydroperoxides induce expression of vascular endothelial growth factor (VEGF) in human colorectal tumor cells. The FASEB Journal, 19(1), 97–99. https://doi.org/10.1096/fj.04-2111fje.PubMedCrossRef

156.

Warner, D. R., Liu, H., Miller, M. E., Ramsden, C. E., Gao, B., Feldstein, A. E., et al. (2017). Dietary linoleic acid and its oxidized metabolites exacerbate liver injury caused by ethanol via induction of hepatic proinflammatory response in mice. The American Journal of Pathology, 187(10), 2232–2245. https://doi.org/10.1016/j.ajpath.2017.06.008.PubMedCrossRefPubMedCentral

157.

Suardíaz, R., Masgrau, L., Lluch, J. M., & González-Lafont, À. (2013). An insight into the regiospecificity of linoleic acid peroxidation catalyzed by mammalian 15-lipoxygenases. The Journal of Physical Chemistry B, 117(14), 3747–3754. https://doi.org/10.1021/jp312747q.PubMedCrossRef

158.

Silverman, A. L., Bronstein, J. C., Krymgold, S., Kahlon, D., & Bull, A. W. (1996). Decreased levels of 13-hydroxyoctadecadienoic acid (13-HODE) dehydrogenase in neoplastic tissue of human colon biopsies. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology, 5(1), 53–56.

159.

Bull, A. W., Branting, C., Bronstein, J. C., Blackburn, M. L., & Rafter, J. (1993). Increases in 13-hydroxyoctadecadienoic acid dehydrogenase activity during differentiation of cultured cells. Carcinogenesis, 14(11), 2239–2243.PubMedCrossRef

160.

Wahli, W., & Michalik, L. (2012). PPARs at the crossroads of lipid signaling and inflammation. Trends in Endocrinology and Metabolism, 23(7), 351–363. https://doi.org/10.1016/j.tem.2012.05.001.PubMedCrossRef

161.

Gou, Q., Gong, X., Jin, J., Shi, J., & Hou, Y. (2017). Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy. Oncotarget, 8(36), 60704–60709. https://doi.org/10.18632/oncotarget.19610.PubMedPubMedCentralCrossRef

162.

Ginderachter, J. A., Movahedi, K., den Bossche, J., & Baetselier, P. (2008). Macrophages, PPARs, and cancer. PPAR Research, 2008. https://doi.org/10.1155/2008/169414.

163.

Peters, J. M., Foreman, J. E., & Gonzalez, F. J. (2011). Dissecting the role of peroxisome proliferatoractivated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis. Cancer Metastasis Reviews, 30(3-4), 619–640. https://doi.org/10.1007/s10555-011-9320-1.PubMedPubMedCentralCrossRef

164.

Qian, Z., Wu, Z., Huang, L., Qiu, H., Wang, L., Li, L., et al. (2015). Mulberry fruit prevents LPS-induced NF-kappaB/pERK/MAPK signals in macrophages and suppresses acute colitis and colorectal tumorigenesis in mice. Scientific Reports, 5. https://doi.org/10.1038/srep17348.

165.

Meterissian, S. H., Forse, R. A., Steele, G. D., & Thomas, P. (1995). Effect of membrane free fatty acid alterations on the adhesion of human colorectal carcinoma cells to liver macrophages and extracellular matrix proteins. Cancer Letters, 89(2), 145–152.PubMedCrossRef

166.

Cook, K. L., Soto-Pantoja, D. R., Clarke, P., Cruz, I. M., Zwart, A., Wärri, A., et al. (2016). Endoplasmic reticulum stress protein GRP78 modulates lipid metabolism to control drug sensitivity and antitumor immunity in breast cancer. Cancer Research, 76(19), 5657–5670. https://doi.org/10.1158/0008-5472.CAN-15-2616.PubMedPubMedCentralCrossRef

167.

Schumann, T., Adhikary, T., Wortmann, A., Finkernagel, F., Lieber, S., Schnitzer, E., et al. (2015). Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. Oncotarget, 6(15), 13416–13433. https://doi.org/10.18632/oncotarget.3826.PubMedPubMedCentralCrossRef

168.

Buckley, C. D., Gilroy, D. W., & Serhan, C. N. (2014). Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity, 40(3), 315–327. https://doi.org/10.1016/j.immuni.2014.02.009.PubMedPubMedCentralCrossRef

169.

Meirer, K., Steinhilber, D., & Proschak, E. (2014). Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. Basic & Clinical Pharmacology & Toxicology, 114(1), 83–91. https://doi.org/10.1111/bcpt.12134.CrossRef

170.

Astudillo, A. M., Balgoma, D., Balboa, M. A., & Balsinde, J. (2012). Dynamics of arachidonic acid mobilization by inflammatory cells. Biochimica et Biophysica Acta, 1821(2), 249–256. https://doi.org/10.1016/j.bbalip.2011.11.006.PubMedCrossRef

171.

Ekambaram, P., Lambiv, W., Cazzolli, R., Ashton, A. W., & Honn, K. V. (2011). The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Reviews, 30(3-4), 397–408. https://doi.org/10.1007/s10555-011-9297-9.PubMedCrossRef

172.

Wang, D., & Dubois, R. N. (2006). Prostaglandins and cancer. Gut, 55(1), 115–122. https://doi.org/10.1136/gut.2004.047100.PubMedPubMedCentralCrossRef

173.

Burke, L., Butler, C. T., Murphy, A., Moran, B., Gallagher, W. M., O'Sullivan, J., et al. (2016). Evaluation of cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer. Frontiers in Cell and Development Biology, 4(103). https://doi.org/10.3389/fcell.2016.00103.

174.

Chandrasekharan, J. A., & Sharma-Walia, N. (2015). Lipoxins: nature's way to resolve inflammation. Journal of Inflammation Research, 8, 181–192. https://doi.org/10.2147/JIR.S90380.PubMedPubMedCentralCrossRef

175.

Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins & Other Lipid Mediators, 96(1-4), 27–36. https://doi.org/10.1016/j.prostaglandins.2011.08.004.CrossRef

176.

Hamabata, T., Nakamura, T., Masuko, S., Maeda, S., & Murata, T. (2018). Production of lipid mediators across different disease stages of dextran sulfate sodium-induced colitis in mice. Journal of Lipid Research, 59(4), 586–595. https://doi.org/10.1194/jlr.M079095.PubMedCrossRef

177.

Netea-Maier, R. T., Smit, J. W. A., & Netea, M. G. (2018). Metabolic changes in tumor cells and tumorassociated macrophages: a mutual relationship. Cancer Letters, 413, 102–109. https://doi.org/10.1016/j.canlet.2017.10.037.PubMedCrossRef

178.

Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(3), 181–193. https://doi.org/10.1038/nrc2809.PubMedPubMedCentralCrossRef

179.

Nakanishi, M., & Rosenberg, D. W. (2013). Multifaceted roles of PGE2 in inflammation and cancer. Seminars in Immunopathology, 35(2), 123–137. https://doi.org/10.1007/s00281-012-0342-8.PubMedCrossRef

180.

Menter, D. G., & Dubois, R. N. (2012). Prostaglandins in cancer cell adhesion, migration, and invasion. International Journal of Cell Biology. https://doi.org/10.1155/2012/723419.

181.

Kambayashi, T., Alexander, H. R., Fong, M., & Strassmann, G. (1995). Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. Journal of Immunology (Baltimore, Md.: 1950), 154(7), 3383–3390.

182.

Fang, M., Li, Y., Huang, K., Qi, S., Zhang, J., Zgodzinski, W., et al. (2017). IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment. Cancer Research, 77(10), 2735–2745. https://doi.org/10.1158/0008-5472.CAN-16-1602.PubMedPubMedCentralCrossRef

183.

Bellamkonda, K., Chandrashekar, N., Osman, J., Selvanesan, B., Savari, S., & Sjölander, A. (2016). The eicosanoids leukotriene D4 and prostaglandin E2 promote the tumorigenicity of colon cancer-initiating cells in a xenograft mouse model. BMC Cancer, 16(1), 425. https://doi.org/10.1186/s12885-016-2466-z.PubMedPubMedCentralCrossRef

184.

Inaba, T., Sano, H., Kawahito, Y., Hla, T., Akita, K., Toda, M., et al. (2003). Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proceedings of the National Academy of Sciences, 100(5), 2736–2741. https://doi.org/10.1073/pnas.0435410100.CrossRef

185.

Moreno, J. J. (2017). Eicosanoid receptors: targets for the treatment of disrupted intestinal epithelial homeostasis. European Journal of Pharmacology, 796, 7–19. https://doi.org/10.1016/j.ejphar.2016.12.004.PubMedCrossRef

186.

Mutoh, M., Watanabe, K., Kitamura, T., Shoji, Y., Takahashi, M., Kawamori, T., et al. (2002). Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Research, 62(1), 28–32.PubMed

187.

Prima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T., & Kusmartsev, S. (2017). COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proceedings of the National Academy of Sciences, 114(5), 1117–1122. https://doi.org/10.1073/pnas.1612920114.CrossRef

188.

Na, Y.-R., Yoon, Y.-N., Son, D.-I., & Seok, S.-H. (2013). Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS ONE, 8(5). https://doi.org/10.1371/journal.pone.0063451.

189.

Heusinkveld, M., de van Steenwijk, P. J., Goedemans, R., Ramwadhdoebe, T. H., Gorter, A., Welters, M. J. P., et al. (2011). M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. The Journal of Immunology, 187(3), 1157–1165. https://doi.org/10.4049/jimmunol.1100889.PubMedCrossRef

190.

Tai, H.-H., Ensor, C., Tong, M., Zhou, H., & Yan, F. (2002). Prostaglandin catabolizing enzymes. Prostaglandins & Other Lipid Mediators, 68, 483–493. https://doi.org/10.1016/S0090-6980(02)00050-3.CrossRef

191.

Tai, H.-H. (2011). Prostaglandin catabolic enzymes as tumor suppressors. Cancer and Metastasis Reviews, 30(3-4), 409–417. https://doi.org/10.1007/s10555-011-9314-z.PubMedCrossRef

192.

Eruslanov, E., Daurkin, I., Ortiz, J., Vieweg, J., & Kusmartsev, S. (2010). Pivotal advance: tumormediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE(2) catabolism in myeloid cells. Journal of Leukocyte Biology, 88(5), 839–848. https://doi.org/10.1189/jlb.1209821.PubMedCrossRef

193.

Eruslanov, E., Kaliberov, S., Daurkin, I., Kaliberova, L., Buchsbaum, D., Vieweg, J., et al. (2009). Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. Journal of Immunology, 182(12), 7548–7557. https://doi.org/10.4049/jimmunol.0802358.CrossRef

194.

Murata, T., & Maehara, T. (2016). Discovery of anti-inflammatory role of prostaglandin D2. The Journal of Veterinary Medical Science, 78(11), 1643–1647. https://doi.org/10.1292/jvms.16-0347.PubMedPubMedCentralCrossRef

195.

Kanaoka, Y., & Urade, Y. (2003). Hematopoietic prostaglandin D synthase. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 69(2-3), 163–167.PubMedCrossRef

196.

Nugteren, D. H., & Hazelhof, E. (1973). Isolation and properties of intermediates in prostaglandin biosynthesis. Biochimica et Biophysica Acta, 326(3), 448–461.PubMedCrossRef

197.

Park, J. M., Kanaoka, Y., Eguchi, N., Aritake, K., Grujic, S., Materi, A. M., et al. (2007). Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. Cancer Research, 67(3), 881–889. https://doi.org/10.1158/0008-5472.CAN-05-3767.PubMedCrossRef

198.

Li, J., Kong, D., Wang, Q., Wu, W., Tang, Y., Bai, T., et al. (2017). Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation. EMBO Molecular Medicine, 9(5), 571–588. https://doi.org/10.15252/emmm.201606987.PubMedPubMedCentralCrossRef

199.

Shibata, T. (2015). 15-Deoxy-Δ12,14-prostaglandin J2 as an electrophilic mediator. Bioscience, Biotechnology, and Biochemistry, 79(7), 1044–1049. https://doi.org/10.1080/09168451.2015.1012149.PubMedCrossRef

200.

Scher, J. U., & Pillinger, M. H. (2005). 15d-PGJ2: the anti-inflammatory prostaglandin? Clinical Immunology, 114(2), 100–109. https://doi.org/10.1016/j.clim.2004.09.008.PubMedCrossRef

201.

Straus, D. S., & Glass, C. K. (2001). Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Medicinal Research Reviews, 21(3), 185–210.PubMedCrossRef

202.

Drew, P. D., & Chavis, J. A. (2001). The cyclopentone prostaglandin 15-deoxy-Delta(12,14) prostaglandin J2 represses nitric oxide, TNF-alpha, and IL-12 production by microglial cells. Journal of Neuroimmunology, 115(1-2), 28–35.PubMedCrossRef

203.

Tsubouchi, Y., Kawahito, Y., Kohno, M., Inoue, K., Hla, T., & Sano, H. (2001). Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta(12,14)-prostaglandin J2. Biochemical and Biophysical Research Communications, 283(4), 750–755. https://doi.org/10.1006/bbrc.2001.4847.PubMedCrossRef

204.

Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998). The peroxisome proliferatoractivated receptor-γ is a negative regulator of macrophage activation. Nature, 391(6662), 34178. https://doi.org/10.1038/34178.CrossRef

205.

Cuzzocrea, S., Ianaro, A., Wayman, N. S., Mazzon, E., Pisano, B., Dugo, L., et al. (2003). The cyclopentenone prostaglandin 15-deoxy-delta(12,14)- PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. British Journal of Pharmacology, 138(4), 678–688. https://doi.org/10.1038/sj.bjp.0705077.PubMedPubMedCentralCrossRef

206.

Kansal, S., Vaiphei, K., & Agnihotri, N. (2014). Alterations in lipid mediated signaling and Wnt/ beta -catenin signaling in DMH induced colon cancer on supplementation of fish oil. BioMed Research International. https://doi.org/10.1155/2014/832025.

207.

Shen, D., Deng, C., & Zhang, M. (2007). Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgraduate Medical Journal, 83(980), 414–419. https://doi.org/10.1136/pmj.2006.052761.PubMedPubMedCentralCrossRef

208.

Hyun, J., Romero, L., Riveron, R., Flores, C., Kanagavelu, S., Chung, K. D., et al. (2015). Human intestinal epithelial cells express interleukin-10 through Toll-like receptor 4-mediated epithelial-macrophage crosstalk. Journal of Innate Immunity, 7(1), 87–101. https://doi.org/10.1159/000365417.PubMedCrossRef

209.

Helliwell, R., Adams, L. F., & Mitchell, M. D. (2004). Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins, Leukotrienes and Essential Fatty Acids, 70(2), 101–113. https://doi.org/10.1016/j.plefa.2003.04.002.CrossRef

210.

Cathcart, M.-C. C., Reynolds, J. V., O'Byrne, K. J., & Pidgeon, G. P. (2010). The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochimica et Biophysica Acta, 1805(2), 153–166. https://doi.org/10.1016/j.bbcan.2010.01.006.PubMedCrossRef

211.

Sasaki, Y., Ochiai, T., Takamura, M., Kondo, Y., Yokoyama, C., & Hara, S. (2017). Role of prostacyclin synthase in carcinogenesis. Prostaglandins & Other Lipid Mediators, 133, 49–52. https://doi.org/10.1016/j.prostaglandins.2017.05.001.CrossRef

212.

Sasaki, Y., Kamiyama, S., Kamiyama, A., Matsumoto, K., Akatsu, M., Nakatani, Y., et al. (2015). Genetic-deletion of cyclooxygenase-2 downstream prostacyclin synthase suppresses inflammatory reactions but facilitates carcinogenesis, unlike deletion of microsomal prostaglandin E Synthase-1. Scientific Reports, 5(1). https://doi.org/10.1038/srep17376.

213.

Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., et al. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 97(24), 13275–13280. https://doi.org/10.1073/pnas.97.24.13275.PubMedPubMedCentralCrossRef

214.

Zuo, X., Peng, Z., Moussalli, M. J., Morris, J. S., Broaddus, R. R., Fischer, S. M., et al. (2009). Targeted genetic disruption of peroxisome proliferator–activated receptor-δ and colonic tumorigenesis. Journal of the National Cancer Institute, 101(10), 762–767. https://doi.org/10.1093/jnci/djp078.PubMedPubMedCentralCrossRef

215.

Nemenoff, R., Meyer, A. M., Hudish, T. M., Mozer, A. B., Snee, A., Narumiya, S., et al. (2008). Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer Prevention Research (Philadelphia, Pa.), 1(5), 349–356. https://doi.org/10.1158/1940-6207.CAPR-08-0145.CrossRef

216.

Tennis, M. A., Vanscoyk, M., Keith, R. L., & Winn, R. A. (2010). The role of prostacyclin in lung cancer. Translational Research, 155(2), 57–61. https://doi.org/10.1016/j.trsl.2009.06.010.PubMedCrossRef

217.

Dwyer-Nield, L., Hickey, G. A., Friedman, M., Choo, K., McArthur, D. G., Tennis, M. A., et al. (2017). The second-generation PGI2 analogue treprostinil fails to chemoprevent tumors in a murine lung adenocarcinoma model. Cancer Prevention Research, 10(11), 671–679. https://doi.org/10.1158/1940-6207.CAPR-17-0050.PubMedCrossRef

218.

Montenegro-Burke, J. R., Sutton, J. A., Rogers, L. M., Milne, G. L., McLean, J. A., & Aronoff, D. M. (2016). Lipid profiling of polarized human monocyte-derived macrophages. Prostaglandins & Other Lipid Mediators, 127, 1–8. https://doi.org/10.1016/j.prostaglandins.2016.11.002.CrossRef

219.

Hamberg, M., Svensson, J., & Samuelsson, B. (1974). Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proceedings of the National Academy of Sciences of the United States of America, 71(10), 3824–3828.PubMedPubMedCentralCrossRef

220.

Sakai, H., Suzuki, T., Takahashi, Y., Ukai, M., Tauchi, K., Fujii, T., et al. (2006). Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Letters, 580(14), 3368–3374. https://doi.org/10.1016/j.febslet.2006.05.007.PubMedCrossRef

221.

Gustafsson, A., Hansson, E., Kressner, U., Nordgren, S., Andersson, M., Lonnroth, C., et al. (2007). Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncologica, 46(8), 1107–1112. https://doi.org/10.1080/02841860701403061.PubMedCrossRef

222.

Li, X., & Tai, H. H. (2013). Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein -1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells. PLoS One, 8(1). doi:https://doi.org/10.1371/journal.pone.0054073

223.

Carter, P. R., McElhatten, R. M., Zhang, S., Wright, W. S., & Harris, N. R. (2011). Thromboxaneprostanoid receptor expression and antagonism in dextran-sodium sulfate-induced colitis. Inflammation Research, 60(1), 87–92. https://doi.org/10.1007/s00011-010-0240-2.PubMedCrossRef

224.

Sato, K., Ohkura, S., Kitahara, Y., Ohama, T., Hori, M., Sato, M., et al. (2007). Involvement of CPI-17 downregulation in the dysmotility of the colon from dextran sodium sulphate-induced experimental colitis in a mouse model. Neurogastroenterology and Motility, 19(6), 504–514. https://doi.org/10.1111/j.1365-2982.2007.00911.x.PubMedCrossRef

225.

Okuno, T., Iizuka, Y., Okazaki, H., Yokomizo, T., Taguchi, R., & Shimizu, T. (2008). 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. The Journal of Experimental Medicine, 205(4), 759–766. https://doi.org/10.1084/jem.20072329.PubMedPubMedCentralCrossRef

226.

Iizuka, Y., Okuno, T., Saeki, K., Uozaki, H., Okada, S., Misaka, T., et al (2010). Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. The FASEB Journal, 24(12), 4678–4690. https://doi.org/10.1096/fj.10-165050.PubMedCrossRef

227.

Capra, V., Rovati, E. G., Mangano, P., Buccellati, C., Murphy, R. C., & Sala, A. (2015). Transcellular biosynthesis of eicosanoid lipid mediators. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1851(4), 377–382. https://doi.org/10.1016/j.bbalip.2014.09.002.CrossRef

228.

Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J. N., Petasis, N. A., et al. (2005). Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proceedings of the National Academy of Sciences of the United States of America, 102(21), 7671–7676. https://doi.org/10.1073/pnas.0409271102.PubMedPubMedCentralCrossRef

229.

Ihara, A., Wada, K., Yoneda, M., Fujisawa, N., Takahashi, H., & Nakajima, A. (2007). Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. Journal of Pharmacological Sciences, 103(1), 24–32.PubMedCrossRef

230.

Gounaris, E., Heiferman, M. J., Heiferman, J. R., Shrivastav, M., Vitello, D., Blatner, N. R., et al (2015). Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation. PLoS One, 10(3). https://doi.org/10.1371/journal.pone.0121402.

231.

Rossi, A., Pergola, C., Koeberle, A., Hoffmann, M., Dehm, F., Bramanti, P., et al. (2010). The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. British Journal of Pharmacology, 161(3), 555–570. https://doi.org/10.1111/j.1476-5381.2010.00930.x.PubMedPubMedCentralCrossRef

232.

Nielsen, O. H., Verspaget, H. W., & Elmgreen, J. (1988). Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Alimentary Pharmacology & Therapeutics, 2(3), 203–211.CrossRef

233.

Naito, Y., Ji, X., Tachibana, S., Aoki, S., Furuya, M., Tazura, Y., et al. (2015). Effects of arachidonic acid intake on inflammatory reactions in dextran sodium sulphate-induced colitis in rats. The British Journal of Nutrition, 114(5), 734–745. https://doi.org/10.1017/S000711451500224X.PubMedCrossRef

234.

Wen, Z., Liu, H., Li, M., Li, B., Gao, W., Shao, Q., et al. (2015). Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumorassociated macrophage infiltration. Oncogene, 34(10), 1241. https://doi.org/10.1038/onc.2014.85.PubMedCrossRef

235.

Nosaka, T., Baba, T., Tanabe, Y., Sasaki, S., Nishimura, T., Imamura, Y., et al. (2018). Alveolar macrophages drive hepatocellular carcinoma lung metastasis by generating leukotriene B4. Journal of Immunology, 200(5), 1839–1852. https://doi.org/10.4049/jimmunol.1700544.CrossRef

236.

Ringleb, J., Strack, E., Angioni, C., Geisslinger, G., Steinhilber, D., Weigert, A., et al. (2017). Apoptotic cancer cells suppress 5-lipoxygenase in tumor-associated macrophages. Journal of Immunology, 200(2), 857–868. https://doi.org/10.4049/jimmunol.1700609.CrossRef

237.

Kanaoka, Y., & Boyce, J. A. (2004). Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. The Journal of Immunology, 173(3), 1503–1510. https://doi.org/10.4049/jimmunol.173.3.1503.PubMedCrossRef

238.

Austen, F. K. (2008). The cysteinyl leukotrienes: where do they come from? What are they? Where are they going? Nature Immunology, 9(2), 113. https://doi.org/10.1038/ni0208-113.PubMedCrossRef

239.

Savari, S. (2014). Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer. World Journal of Gastroenterology, 20(4), 968. https://doi.org/10.3748/wjg.v20.i4.968.PubMedPubMedCentralCrossRef

240.

Savari, S., Chandrashekar, N., Osman, J., Douglas, D., Bellamkonda, K., Jönsson, G., et al. (2016). Cysteinyl leukotriene 1 receptor influences intestinal polyp incidence in a gender-specific manner in the Apc Min/+ mouse model. Carcinogenesis, 37(5), 491–499. https://doi.org/10.1093/carcin/bgw031.PubMedCrossRef

241.

Savari, S., Liu, M., Zhang, Y., Sime, W., & Sjölander, A. (2013). CysLT1R antagonists inhibit tumor growth in a xenograft model of colon cancer. PLoS ONE, 8(9). doi:https://doi.org/10.1371/journal.pone.0073466

242.

Magnusson, C., Mezhybovska, M., Lörinc, E., Fernebro, E., Nilbert, M., & Sjölander, A. (2010). Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. European Journal of Cancer, 46(4), 826–835. https://doi.org/10.1016/j.ejca.2009.12.022.PubMedCrossRef

243.

Nishikawa, M., Hikasa, Y., Hori, K., Tanida, N., & Shimoyama, T. (1995). Effect of leukotriene C4D4 antagonist on colonic damage induced by intracolonic administration of trinitrobenzene sulfonic acid in rats. Journal of Gastroenterology, 30(1), 34–40. https://doi.org/10.1007/BF01211372.PubMedCrossRef

244.

Mehdawi, L. M., Satapathy, S. R., Gustafsson, A., Lundholm, K., Alvarado-Kristensson, M., & Sjölander, A. (2017). A potential anti-tumor effect of leukotriene C4 through the induction of 15-hydroxyprostaglandin dehydrogenase expression in colon cancer cells. Oncotarget, 8(21), 35033–35047. https://doi.org/10.18632/oncotarget.16591.PubMedPubMedCentralCrossRef

245.

Zhang, Y. (2013). Crosstalk between colorectal Cancer Cells and tumor associated macrophages. Doctoral Dissertation, Lund University. pp 1–60. http://portal.research.lu.se/portal/en/publications/crosstalkbetween-colorectal-cancer-cells-and-tumourassociated-macrophages(7f4f9cf7-ac9f-4eaf-b82bbc4ca966267e).html

246.

Zhang, Y., Sime, W., Juhas, M., & Sjölander, A. (2013). Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. European Journal of Cancer, 49(15), 3320–3334. https://doi.org/10.1016/j.ejca.2013.06.005.PubMedCrossRef

247.

Vinnakota, K., Zhang, Y., Selvanesan, B., Topi, G., Salim, T., Sand-Dejmek, J., et al. (2017). M2-like macrophages induce colon cancer cell invasion via matrix metalloproteinases. Journal of Cellular Physiology, 232(12), 3468–3480. https://doi.org/10.1002/jcp.25808.PubMedCrossRef

248.

Osman, J., Savari, S., Chandrashekar, N. K., Bellamkonda, K., Douglas, D., & Sjolander, A. (2017). Cysteinyl leukotriene receptor 1 facilitates tumorigenesis in a mouse model of colitis-associated colon cancer. Oncotarget, 8(21), 34773–34786. https://doi.org/10.18632/oncotarget.16718.PubMedPubMedCentralCrossRef

249.

Lukic, A., Ji, J., Idborg, H., Samuelsson, B., Palmberg, L., Gabrielsson, S., et al. (2016). Pulmonary epithelial cancer cells and their exosomes metabolize myeloid cell-derived leukotriene C4 to leukotriene D4. Journal of Lipid Research, 57(9), 1659–1669. https://doi.org/10.1194/jlr.M066910.PubMedPubMedCentralCrossRef

250.

Kim, J. H., Tagari, P., Griffiths, A. M., Ford-Hutchinson, A., Smith, C., & Sherman, P. M. (1995). Levels of peptidoleukotriene E4 are elevated in active Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition, 20(4), 403–407.PubMedCrossRef

251.

Sharon, P., & Stenson, W. F. (1984). Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology, 86(3), 453–460.PubMed

252.

Moreno, J. J. (2009). New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochemical Pharmacology, 77(1), 1–10. https://doi.org/10.1016/j.bcp.2008.07.033.PubMedCrossRef

253.

Neilson, A. P., Ren, J., Hong, Y. H., Sen, A., Smith, W. L., Brenner, D. E., et al. (2012). Effect of fish oil on levels of R- and S-enantiomers of 5-, 12-, and 15-hydroxyeicosatetraenoic acids in mouse colonic mucosa. Nutrition and Cancer, 64(1), 163–172. https://doi.org/10.1080/01635581.2012.630168.PubMedCrossRef

254.

Tang, K., Cai, Y., Joshi, S., Tovar, E., Tucker, S. C., Maddipati, K., et al. (2015). Convergence of eicosanoid and integrin biology: 12-lipoxygenase seeks a partner. Molecular Cancer, 14(1), 1–13. https://doi.org/10.1186/s12943-015-0382-5.CrossRef

255.

Jiang, Y., Pan, Y., Rhea, P. R., Tan, L., Gagea, M., Cohen, L., et al. (2016). A sucrose-enriched diet promotes tumorigenesis in mammary gland in part through the 12-lipoxygenase pathway. Cancer Research, 76(1), 24–29. https://doi.org/10.1158/0008-5472.can-14-3432.PubMedPubMedCentralCrossRef

256.

Ye, Y. N., Liu, E. S., Shin, V. Y., Wu, W. K., & Cho, C. H. (2004). Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology, 203(1-3), 179–188. https://doi.org/10.1016/j.tox.2004.06.004.PubMedCrossRef

257.

de Carvalho, D. D., Sadok, A., Bourgarel-Rey, V., Gattacceca, F., Penel, C., Lehmann, M., et al. (2008). Nox1 downstream of 12-lipoxygenase controls cell proliferation but not cell spreading of colon cancer cells. International Journal of Cancer, 122(8), 1757–1764. https://doi.org/10.1002/ijc.23300.PubMedCrossRef

258.

Steinhilber, D., Fischer, A., Metzner, J., Steinbrink, S., Roos, J., Ruthardt, M., et al. (2010). 5-Lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Frontiers in Pharmacology, 1, 143. https://doi.org/10.3389/fphar.2010.00143.PubMedPubMedCentralCrossRef

259.

Rabinovitch, H., Durand, J., Rigaud, M., Mendy, F., & Breton, J. C. (1981). Transformation of arachidonic acid into monohydroxy-eicosatetraenoic acids by mouse peritoneal macrophages. Lipids, 16(7), 518–524.PubMedCrossRef

260.

Serhan, C. N., Levy, B. D., Clish, C. B., Gronert, K., & Chiang, N. (2000). Lipoxins, aspirin-triggered 15-epilipoxin stable analogs and their receptors in anti-inflammation: a window for therapeutic opportunity. Ernst Schering Research Foundation Workshop, 31, 143–185.

261.

Janakiram, N. B., Mohammed, A., & Rao, C. V. (2011). Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Reviews, 30(3-4), 507–523. https://doi.org/10.1007/s10555-011-9311-2.PubMedCrossRef

262.

Janakiram, N. B., & Rao, C. V. (2009). Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Current Molecular Medicine, 9(5), 565–579.PubMedCrossRef

263.

Vong, L., Ferraz, J. G., Dufton, N., Panaccione, R., Beck, P. L., Sherman, P. M., et al. (2012). Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One, 7(6). https://doi.org/10.1371/journal.pone.0039244

264.

Chen, K., Liu, M., Liu, Y., Yoshimura, T., Shen, W., Le, Y., et al. (2013). Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. The Journal of Clinical Investigation, 123(4), 1694–1704. https://doi.org/10.1172/JCI65569.PubMedPubMedCentralCrossRef

265.

Kure, I., Nishiumi, S., Nishitani, Y., Tanoue, T., Ishida, T., Mizuno, M., et al. (2010). Lipoxin A(4) reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation. The Journal of Pharmacology and Experimental Therapeutics, 332(2), 541–548. https://doi.org/10.1124/jpet.109.159046.PubMedCrossRef

266.

Chen, Y., Hao, H., He, S., Cai, L., Li, Y., Hu, S., et al. (2010). Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Molecular Cancer Therapeutics, 9(8), 2164–2174. https://doi.org/10.1158/1535-7163.MCT-10-0173.PubMedCrossRef

267.

Simões, R. L., De-Brito, N. M., Cunha-Costa, H., Morandi, V., Fierro, I. M., Roitt, I. M., et al. (2016). Lipoxin A4 selectively programs the profile of m2 tumor-associated macrophages which favour control of tumor progression. International Journal of Cancer, 140(2), 346–357. https://doi.org/10.1002/ijc.30424.PubMedCrossRef

268.

Pierdomenico, A., Recchiuti, A., Simiele, F., Codagnone, M., Mari, V., Davì, G., et al. (2015). MicroRNA-181b regulates ALX/FPR2 receptor expression and proresolution signaling in human macrophages. Journal of Biological Chemistry, 290(6), 3592–3600. https://doi.org/10.1074/jbc.M114.592352.PubMedCrossRef

269.

Prieto, P., Cuenca, J., Través, P. G., Fernández-Velasco, M., Martín-Sanz, P., & Boscá, L. (2010). Lipoxin A4 impairment of apoptotic signaling in macrophages: implication of the PI3K/Akt and the ERK/Nrf-2 defense pathways. Cell Death and Differentiation, 17(7), 1179–1188. https://doi.org/10.1038/cdd.2009.220.PubMedCrossRef

270.

Panigrahy, D., Greene, E. R., Pozzi, A., Wang, D. W., & Zeldin, D. C. (2011). EET signaling in cancer. Cancer Metastasis Reviews, 30(3-4), 525–540. https://doi.org/10.1007/s10555-011-9315-y.PubMedPubMedCentralCrossRef

271.

Panigrahy, D., Kaipainen, A., Greene, E. R., & Huang, S. (2010). Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer and Metastasis Reviews, 29(4), 723–735. https://doi.org/10.1007/s10555-010-9264-x.PubMedCrossRef

272.

Zhang, W., Li, H., Dong, H., Liao, J., Hammock, B. D., & Yang, G. Y. (2013). Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice. Anticancer Research, 33(12), 5261–5271.PubMedPubMedCentral

273.

Shahidi, F., & Ambigaipalan, P. (2018). Omega-3 polyunsaturated fatty acids and their health benefits. Annual Review of Food Science and Technology, 9, 345–381. https://doi.org/10.1146/annurev-food-111317-095850.PubMedCrossRef

274.

Weylandt, K. H., Serini, S., Chen, Y. Q., Su, H.-M. M., Lim, K., Cittadini, A., et al. (2015). Omega-3 polyunsaturated fatty acids: the way forward in times of mixed evidence. BioMed Research International. https://doi.org/10.1155/2015/143109.

275.

Larsson, S. C., Kumlin, M., Ingelman-Sundberg, M., & Wolk, A. (2004). Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. The American Journal of Clinical Nutrition, 79(6), 935–945. https://doi.org/10.1093/ajcn/79.6.935.PubMedCrossRef

276.

MacLean, C. H., Newberry, S. J., Mojica, W. A., Khanna, P., Issa, A. M., Suttorp, M. J., et al. (2006). Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA, 295(4), 403–415. https://doi.org/10.1001/jama.295.4.403.PubMedCrossRef

277.

Park, J.-M., Kwon, S.-H., Han, Y.-M., Hahm, K.-B., & Kim, E.-H. (2013). Omega-3 polyunsaturated fatty acids as potential chemopreventive agent for gastrointestinal cancer. Journal of Cancer Prevention, 18(3), 201–208. https://doi.org/10.15430/JCP.2013.18.3.201.PubMedPubMedCentralCrossRef

278.

Miccadei, S., Masella, R., Mileo, A., & Gessani, S. (2016). ω3 polyunsaturated fatty acids as immunomodulators in colorectal cancer: new potential role in adjuvant therapies. Frontiers in Immunology, 7. https://doi.org/10.3389/fimmu.2016.00486.

279.

Lee, J., Sim, T.-B., Lee, J.-e., & Na, H.-K. (2017). Chemopreventive and chemotherapeutic effects of fish oil derived omega-3 polyunsaturated fatty acids on colon carcinogenesis. Clinical Nutrition Research, 6(3), 147–160. https://doi.org/10.7762/cnr.2017.6.3.147.PubMedPubMedCentralCrossRef

280.

Siscovick, D. S., Barringer, T. A., Fretts, A. M., Wu, J. H. Y., Lichtenstein, A. H., Costello, R. B., et al. (2017). Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease. Circulation, 135(15). https://doi.org/10.1161/CIR.0000000000000482.

281.

Yum, H.-W. W., Na, H.-K. K., & Surh, Y.-J. J. (2016). Anti-inflammatory effects of docosahexaenoic acid: implications for its cancer chemopreventive potential. Seminars in Cancer Biology, 40-41, 141–159. https://doi.org/10.1016/j.semcancer.2016.08.004.PubMedCrossRef

282.

McManus, S., Tejera, N., Awwad, K., Vauzour, D., Rigby, N., Fleming, I., et al. (2016). Differential effects of EPA versus DHA on postprandial vascular function and the plasma oxylipin profile in men. Journal of Lipid Research, 57(9), 1720–1727. https://doi.org/10.1194/jlr.M067801.PubMedPubMedCentralCrossRef

283.

Mason, P. R., & Sherratt, S. (2017). Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochemical and Biophysical Research Communications, 483(1), 425–429. https://doi.org/10.1016/j.bbrc.2016.12.127.PubMedCrossRef

284.

Sherratt, S., & Mason, P. R. (2018). Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction. Chemistry and Physics of Lipids, 212, 73–79. https://doi.org/10.1016/j.chemphyslip.2018.01.002.PubMedCrossRef

285.

Cockbain, A. J., Toogood, G. J., & Hull, M. A. (2012). Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut, 61(1), 135–149. https://doi.org/10.1136/gut.2010.233718.PubMedCrossRef

286.

Cockbain, A. J., Volpato, M., Race, A. D., Munarini, A., Fazio, C., Belluzzi, A., et al. (2014). Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut, 63(11), 1760–1768. https://doi.org/10.1136/gutjnl-2013-306445.PubMedCrossRef

287.

Brinton, E. A., & Mason, P. R. (2017). Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids in Health and Disease, 16(1), 23. https://doi.org/10.1186/s12944-017-0415-8.PubMedPubMedCentralCrossRef

288.

Stables, M. J., Shah, S., Camon, E. B., Lovering, R. C., Newson, J., Bystrom, J., et al. (2011). Transcriptomic analyses of murine resolution-phase macrophages. Blood, 118(26), 192–208. https://doi.org/10.1182/blood-2011-04-345330.CrossRef

289.

Uderhardt, S., & Krönke, G. (2012). 12/15-Lipoxygenase during the regulation of inflammation, immunity, and self-tolerance. Journal of Molecular Medicine, 90(11), 1247–1256. https://doi.org/10.1007/s00109-012-0954-4.PubMedCrossRef

290.

Woodworth, H. L., McCaskey, S. J., Duriancik, D. M., Clinthorne, J. F., Langohr, I. M., Gardner, E. M., et al. (2010). Dietary fish oil alters T lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis. Cancer Research, 70(20), 7960–7969. https://doi.org/10.1158/0008-5472.CAN-10-1396.PubMedCrossRef

291.

Dalli, J. (2017). Does promoting resolution instead of inhibiting inflammation represent the new paradigm in treating infections? Molecular Aspects of Medicine, 58, 12–20. https://doi.org/10.1016/j.mam.2017.03.007.PubMedCrossRef

292.

Jaudszus, A., Gruen, M., Watzl, B., Ness, C., Roth, A., Lochner, A., et al. (2013). Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells. Journal of Lipid Research, 54(4), 923–935. https://doi.org/10.1194/jlr.P031260.PubMedPubMedCentralCrossRef

293.

Serhan, C. N., Chiang, N., & Dalli, J. (2015). The resolution code of acute inflammation: novel proresolving lipid mediators in resolution. Seminars in Immunology, 27(3), 200–215. https://doi.org/10.1016/j.smim.2015.03.004.PubMedPubMedCentralCrossRef

294.

Yang, P., Jiang, Y., & Fischer, S. M. (2014). Prostaglandin E3 metabolism and cancer. Cancer Letters, 348(1-2), 1–11. https://doi.org/10.1016/j.canlet.2014.03.010.PubMedPubMedCentralCrossRef

295.

Terano, T., Salmon, J. A., & Moncada, S. (1984). Biosynthesis and biological activity of leukotriene B5. Prostaglandins, 27(2), 217–232.PubMedCrossRef

296.

Bagga, D., Wang, L., Farias-Eisner, R., Glaspy, J. A., & Reddy, S. T. (2003). Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proceedings of the National Academy of Sciences, 100(4), 1751–1756. https://doi.org/10.1073/pnas.0334211100.CrossRef

297.

Norris, P. C., & Dennis, E. A. (2012). Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. Proceedings of the National Academy of Sciences, 109(22), 8517–8522. https://doi.org/10.1073/pnas.1200189109.CrossRef

298.

Sorensen, L. S., Thorlacius-Ussing, O., Rasmussen, H. H., Lundbye-Christensen, S., Calder, P. C., Lindorff-Larsen, K., et al. (2014). Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B4 and leukotriene B5 production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. Nutrients, 6(10), 4043–4057. https://doi.org/10.3390/nu6104043.PubMedPubMedCentralCrossRef

299.

Bachi, A., Kim, F., Nonogaki, S., Carneiro, C., Lopes, J., Jasiulionis, M., et al. (2009). Leukotriene B4 creates a favorable microenvironment for murine melanoma growth. Molecular Cancer Research, 7(9), 1417–1424. https://doi.org/10.1158/1541-7786.MCR-09-0038.PubMedCrossRef

300.

Kobayashi, J., Yokoyama, S., & Kitamura, S. (1995). Eicosapentaenoic acid modulates arachidonic acid metabolism in rat alveolar macrophages. Prostaglandins, Leukotrienes and Essential Fatty Acids, 52(4), 259–262. https://doi.org/10.1016/0952-3278(95)90047-0.CrossRef

301.

Saku, N., Kobayashi, J., & Kitamura, S. (1999). Eicosapentaenoic acid modulates arachidonic acid metabolism in rat alveolar macrophages activated by silica. Prostaglandins, Leukotrienes and Essential Fatty Acids, 61(1), 51–54. https://doi.org/10.1054/plef.1999.0073.CrossRef

302.

Lukic, A., Larssen, P., Fauland, A., Samuelsson, B., Wheelock, C. E., Gabrielsson, S., et al. (2017). GM-CSF- and M-CSF-primed Mϕ s present similar resolving but distinct inflammatory lipid mediator signatures. The FASEB Journal, 31(10), 4370–4381. https://doi.org/10.1096/fj.201700319R.PubMedCrossRef

303.

Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., et al. (1999). Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature, 400(6742), 378. https://doi.org/10.1038/22572.PubMedCrossRef

304.

Spanbroek, R., Hildner, M., Köhler, A., Müller, A., Zintl, F., Kühn, H., et al (2001). IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proceedings of the National Academy of Sciences, 98(9), 5152–5157. https://doi.org/10.1073/pnas.091076998.CrossRef

305.

Li, X., Yu, Y., & Funk, C. D. (2013). Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4). The FASEB Journal, 27(12), 4987–4997. https://doi.org/10.1096/fj.13-235333.PubMedCrossRef

306.

Liang, P., Henning, S. M., Schokrpur, S., Wu, L., Doan, N., Said, J., et al. (2016). Effect of dietary omega-3 fatty acids on tumor-associated macrophages and prostate cancer progression. The Prostate, 76(14), 1293–1302. https://doi.org/10.1002/pros.23218.PubMedPubMedCentralCrossRef

307.

Bystrom, J., Evans, I., Newson, J., Stables, M., Toor, I., van Rooijen, N., et al. (2008). Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood, 112(10), 4117–4127. https://doi.org/10.1182/blood-2007-12-129767.PubMedPubMedCentralCrossRef

308.

Sulciner, M. L., Serhan, C. N., Gilligan, M. M., Mudge, D. K., Chang, J., Gartung, A., et al. (2017). Resolvins suppress tumor growth and enhance cancer therapy. The Journal of Experimental Medicine, 215(1), 115–140. https://doi.org/10.1084/jem.20170681.PubMedCrossRef

309.

Schwanke, R., Marcon, R., Bento, A., & Calixto, J. B. (2016). EPA- and DHA-derived resolvins’ actions in inflammatory bowel disease. European Journal of Pharmacology, 785, 156–164. https://doi.org/10.1016/j.ejphar.2015.08.050.PubMedCrossRef

310.

Ungaro, F., Rubbino, F., Danese, S., & D’Alessio, S. (2017). Actors and factors in the resolution of intestinal inflammation: lipid mediators as a new approach to therapy in inflammatory bowel diseases. Frontiers in Immunology, 8. https://doi.org/10.3389/fimmu.2017.01331.

311.

Ishida, T., Yoshida, M., Arita, M., Nishitani, Y., Nishiumi, S., Masuda, A., et al. (2010). Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflammatory Bowel Diseases, 16(1), 87. https://doi.org/10.1002/ibd.21029.PubMedPubMedCentralCrossRef

312.

Bento, A. F., Claudino, R. F., Dutra, R. C., Marcon, R., & Calixto, J. B. B. (2011). Omega-3 fatty acidderived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. Journal of Immunology, 187(4), 1957–1969. https://doi.org/10.4049/jimmunol.1101305.CrossRef

313.

Chiu, C.-Y., Gomolka, B., Dierkes, C., Huang, N. R., Schroeder, M., Purschke, M., et al. (2012). Omega-6 docosapentaenoic acid-derived resolvins and 17-hydroxydocosahexaenoic acid modulate macrophage function and alleviate experimental colitis. Inflammation Research, 61(9), 967–976. https://doi.org/10.1007/s00011-012-0489-8.PubMedCrossRef

314.

Kühl, A. A., Erben, U., Kredel, L. I., & Siegmund, B. (2015). Diversity of intestinal macrophages in inflammatory bowel diseases. Frontiers in Immunology, 6. https://doi.org/10.3389/fimmu.2015.00613.

315.

Schmid, M., Gemperle, C., Rimann, N., & Hersberger, M. (2016). Resolvin D1 polarizes primary human macrophages toward a proresolution phenotype through GPR32. Journal of Immunology, 196(8), 3429–3437. https://doi.org/10.4049/jimmunol.1501701.CrossRef

316.

Lee, H.-N., & Surh, Y.-J. (2013). Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis. Biochemical Pharmacology, 86(6), 759–769. https://doi.org/10.1016/j.bcp.2013.07.002.PubMedCrossRef

317.

Serhan, C. N., Chiang, N., & Dalli, J. (2014). Macrophages and the entrance of resolution phase lipid mediators. In S.K. Biswas, and A. Mantovani (Eds.), Macrophages: biology and role in the pathology of diseases (pp. 287–314). doi:https://doi.org/10.1007/978-1-4939-1311-4_13.

318.

Kang, G.-J., Lee, H.-J., Kang, Y., Kim, E., Kim, H., Byun, H., et al (2015). High-mobility group box 1 suppresses resolvin D1-induced phagocytosis via induction of resolvin D1-inactivating enzyme, 15-hydroxyprostaglandin dehydrogenase. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1852(9), 1981–1988. https://doi.org/10.1016/j.bbadis.2015.07.005.CrossRef

319.

Hsiao, H.-M., Sapinoro, R. E., Thatcher, T. H., Croasdell, A., Levy, E. P., Fulton, R. A., et al. (2013). A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS One, 8(3). doi:https://doi.org/10.1371/journal.pone.0058258.

320.

Croasdell, A., Thatcher, T. H., Kottmann, R., Colas, R. A., Dalli, J., Serhan, C. N., et al. (2015). Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. American Journal of Physiology - Lung Cellular and Molecular Physiology, 309(8), L888–L901. https://doi.org/10.1152/ajplung.00125.2015.PubMedPubMedCentralCrossRef

321.

Fredman, G., Ozcan, L., Spolitu, S., Hellmann, J., Spite, M., Backs, J., et al. (2014). Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proceedings of the National Academy of Sciences, 111(40), 14530–14535. https://doi.org/10.1073/pnas.1410851111.CrossRef

322.

Fedirko, V., McKeown-Eyssen, G., Serhan, C. N., Barry, E. L., Sandler, R. S., Figueiredo, J. C., et al. (2017). Plasma lipoxin A4 and resolvin D1 are not associated with reduced adenoma risk in a randomized trial of aspirin to prevent colon adenomas. Molecular Carcinogenesis, 56(8), 1977–1983. https://doi.org/10.1002/mc.22629.PubMedPubMedCentralCrossRef

323.

Herová, M., Schmid, M., Gemperle, C., & Hersberger, M. (2015). ChemR23, the receptor for chemerin and resolvin E1, is expressed and functional on M1 but not on M2 macrophages. Journal of Immunology (Baltimore, Md. : 1950), 194(5), 2330–2337. https://doi.org/10.4049/jimmunol.1402166.CrossRef

324.

Campbell, E. L., Louis, N. A., Tomassetti, S. E., Canny, G. O., Arita, M., Serhan, C. N., et al. (2007). Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. The FASEB Journal, 21(12), 3162–3170. https://doi.org/10.1096/fj.07-8473com.PubMedCrossRef

325.

Wang, R. X., & Colgan, S. P. (2017). Special pro-resolving mediator (SPM) actions in regulating gastrointestinal inflammation and gut mucosal immune responses. Molecular Aspects of Medicine, 58, 93–101. https://doi.org/10.1016/j.mam.2017.02.002.PubMedPubMedCentralCrossRef

326.

Sima, C., Montero, E., Nguyen, D., Freire, M., Norris, P., Serhan, C. N., et al. (2017). ERV1 overexpression in myeloid cells protects against high fat diet induced obesity and glucose intolerance. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-13185-7.

327.

Chiang, N., & Serhan, C. N. (2017). Structural elucidation and physiologic functions of specialized proresolving mediators and their receptors. Molecular Aspects of Medicine, 58, 114–129. https://doi.org/10.1016/j.mam.2017.03.005.PubMedCrossRef

328.

Dalli, J., Zhu, M., Vlasenko, N. A., Deng, B., Haeggström, J. Z., Petasis, N. A., et al. (2013). The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 27(7), 2573–2583. https://doi.org/10.1096/fj.13-227728.CrossRef

329.

Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., et al. (2009). Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. The Journal of Experimental Medicine, 206(1), 15–23. https://doi.org/10.1084/jem.20081880.PubMedPubMedCentralCrossRef

330.

Serhan, C. N., Dalli, J., Karamnov, S., Choi, A., Park, C.-K., Xu, Z.-Z., et al. (2012). Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. The FASEB Journal, 26(4), 1755–1765. https://doi.org/10.1096/fj.11-201442.PubMedPubMedCentralCrossRef

331.

Serhan, C. N., Dalli, J., Colas, R. A., Winkler, J. W., & Chiang, N. (2015). Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochimica et Biophysica Acta, 1851(4), 397–413. https://doi.org/10.1016/j.bbalip.2014.08.006.PubMedCrossRef

332.

Dalli, J., Vlasakov, I., Riley, I. R., Rodriguez, A. R., Spur, B. W., Petasis, N. A., et al. (2016). Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages. Proceedings of the National Academy of Sciences, 113(43), 12232–12237. https://doi.org/10.1073/pnas.1607003113.CrossRef

333.

Marcon, R., Bento, A. F., Dutra, R. C., Bicca, M. A., Leite, D. F. P., & Calixto, J. B. (2013). Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. The Journal of Immunology, 191(8), 4288–4298. https://doi.org/10.4049/jimmunol.1202743.PubMedCrossRef

334.

Abdulnour, R.-E. E., Dalli, J., Colby, J. K., Krishnamoorthy, N., Timmons, J. Y., Tan, S., et al. (2014). Maresin 1 biosynthesis during platelet–neutrophil interactions is organ-protective. Proceedings of the National Academy of Sciences, 111(46), 16526–16531. https://doi.org/10.1073/pnas.1407123111.CrossRef

335.

Deng, B., Wang, C.-W., Arnardottir, H. H., Li, Y., Cheng, C.-Y., Dalli, J., et al. (2014). Maresin biosynthesis and identification of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages. PLoS ONE, 9(7). doi:https://doi.org/10.1371/journal.pone.0102362.

336.

Colas, R. A., Dalli, J., Chiang, N., Vlasakov, I., Sanger, J. M., Riley, I. R., et al. (2016). Identification and actions of the maresin 1 metabolome in infectious inflammation. The Journal of Immunology, 197(11), 4444–4452. https://doi.org/10.4049/jimmunol.1600837.PubMedCrossRef

337.

Hong, S., Gronert, K., Devchand, P. R., Moussignac, R.-L., & Serhan, C. N. (2003). Novel docosatrienes and 17s-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells AUTACOIDS IN ANTI-INFLAMMATION. Journal of Biological Chemistry, 278(17), 14677–14687. https://doi.org/10.1074/jbc.M300218200.PubMedCrossRef

338.

Serhan, C. N., Gotlinger, K., Hong, S., Lu, Y., Siegelman, J., Baer, T., et al. (2006). Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. The Journal of Immunology, 176(3), 1848–1859. https://doi.org/10.4049/jimmunol.176.3.1848.PubMedCrossRef

339.

Masterson, J. C., McNamee, E. N., Fillon, S. A., Hosford, L., Harris, R., Fernando, S. D., et al. (2014). Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis. Gut, 64(8), 1236–1247. https://doi.org/10.1136/gutjnl-2014-306998.PubMedPubMedCentralCrossRef

340.

Schwab, J. M., Chiang, N., Arita, M., & Serhan, C. N. (2007). Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature, 447(7146), 869–874. https://doi.org/10.1038/nature05877.PubMedPubMedCentralCrossRef

341.

Xia, H., Chen, L., Liu, H., Sun, Z., Yang, W., Yang, Y., et al. (2017). Protectin DX increases survival in a mouse model of sepsis by ameliorating inflammation and modulating macrophage phenotype. Scientific Reports, 7(1). doi:https://doi.org/10.1038/s41598-017-00103-0.

342.

Ramon, S., Dalli, J., Sanger, J. M., Winkler, J. W., Aursnes, M., Tungen, J. E., et al. (2016). The protectin PCTR1 is produced by human M2 macrophages and enhances resolution of infectious inflammation. The American Journal of Pathology, 186(4), 962–973. https://doi.org/10.1016/j.ajpath.2015.12.012.PubMedPubMedCentralCrossRef

343.

Dalli, J., Colas, R. A., Arnardottir, H., & Serhan, C. N. (2017). Vagal regulation of group 3 innate lymphoid cells and the immunoresolvent PCTR1 controls infection resolution. Immunity, 46(1), 92–105. https://doi.org/10.1016/j.immuni.2016.12.009.PubMedPubMedCentralCrossRef

344.

Weylandt, K.-H. (2016). Docosapentaenoic acid derived metabolites and mediators—the new world of lipid mediator medicine in a nutshell. European Journal of Pharmacology, 785, 108–115. https://doi.org/10.1016/j.ejphar.2015.11.002.PubMedCrossRef

345.

Vik, A., Dalli, J., & Hansen, T. (2017). Recent advances in the chemistry and biology of anti-inflammatory and specialized pro-resolving mediators biosynthesized from n-3 docosapentaenoic acid. Bioorganic & Medicinal Chemistry Letters, 27(11), 2259–2266. https://doi.org/10.1016/j.bmcl.2017.03.079.CrossRef

346.

Dalli, J., Colas, R. A., & Serhan, C. N. (2013). Novel n-3 immunoresolvents: structures and actions. Scientific Reports, 3. https://doi.org/10.1038/srep01940.

347.

Gobbetti, T., Dalli, J., Colas, R. A., Canova, D., Aursnes, M., Bonnet, D., et al. (2017). Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection. Proceedings of the National Academy of Sciences, 114(15), 3963–3968. https://doi.org/10.1073/pnas.1617290114.CrossRef

348.

Fessler, E., & Medema, J. (2016). Colorectal cancer subtypes: developmental origin and microenvironmental regulation. Trends in Cancer, 2(9), 505–518. https://doi.org/10.1016/j.trecan.2016.07.008.PubMedCrossRef

349.

Efremova, M., Rieder, D., Klepsch, V., Charoentong, P., Finotello, F., Hackl, H., et al. (2018). Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nature Communications, 9(1), 32. https://doi.org/10.1038/s41467-017-02424-0.PubMedPubMedCentralCrossRef

350.

Pace, S., Sautebin, L., & Werz, O. (2017). Sex-biased eicosanoid biology: impact for sex differences in inflammation and consequences for pharmacotherapy. Biochemical Pharmacology 145. doi:https://doi.org/10.1016/j.bcp.2017.06.128.

351.

Gupta, S., Kihara, Y., Maurya, M. R., Norris, P. C., Dennis, E. A., & Subramaniam, S. (2016). Computational modeling of competitive metabolism between ω3- and ω6-polyunsaturated fatty acids in inflammatory macrophages. The Journal of Physical Chemistry B, 120(33), 8346–8353. https://doi.org/10.1021/acs.jpcb.6b02036.PubMedPubMedCentralCrossRef

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Oxygenated lipid signaling in tumor-associated macrophages—focus on colon cancer

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2018

Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma

Preface

The role of lipid signaling in the progression of malignant melanoma

The importance of 15-lipoxygenase inhibitors in cancer treatment